Contribute Try STAT+ Today

One of biotech’s most respected entrepreneurs is betting the novel coronavirus won’t be the last deadly outbreak in his lifetime — and that vaccines won’t be enough to stop a future pandemic from bringing the world to a halt once more.

Tillman Gerngross, the Dartmouth bioengineering professor behind the biotech company Adimab, has founded a new firm dedicated to making antibodies that could protect against the novel coronavirus, called SARS-CoV-2, in addition to any future coronaviruses that might make the leap from animals to humans.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • Today, front page story in the San Francisco Chronicle describes researchers finding that antibodies of Covid 19 fade away soner than expected, making a case for symptom treatment therapies.

Comments are closed.